India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.
A top UN official said the global AIDS epidemic could be over by 2030 because of progress made in treatment and control of the disease.
(Medical Xpress)—People given a choice between generic or branded drugs should look closely at the ingredients in the drug they are buying, argue economists from Deakin University's Graduate School of Business.
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.
Competition from generic drugs continued to hammer French pharmaceutical group Sanofi in the second quarter, the company said Thursday, warning that its full-year earnings could be twice as bad as previous guidance.
U.S. drugmaker Perrigo agreed Monday to buy Ireland's Elan for $8.6 billion in a deal that should allow the rapidly growing company to reduce its tax bill and boost its royalty stream.
(AP)—Two senators want to do away with the agreements that pharmaceutical companies make with one another to keep lower-priced generic copies of brand-name drugs off the market.
New potentially life-saving HIV drugs are "beyond reach" due to restrictive patents, Doctors Without Borders (MSF) said Tuesday, even though basic medication for the disease has become cheaper.
(HealthDay)—In 2012, avoidable health care costs in the United States exceeded $200 billion, according to a report published by the IMS Institute for Healthcare Informatics.
Manufacturers of generic drugs cannot be sued for adverse side effects caused by products that they did not themselves design, the US Supreme Court ruled on Monday.
The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...
Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix.
Medicare beneficiaries with diabetes are two to three times more likely to use expensive brand-name drugs than a comparable group of patients treated within the VA Healthcare System, according to a nationwide study by researchers ...
Evergreening strategies—where pharmaceutical companies slightly change the formulation of their brand drug into "follow on" drugs by combining formulations or producing slow-release forms, for example, so that they can ...
India, known as the "pharmacy to the world", Monday defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.